Publicacións en colaboración con investigadores/as de University of British Columbia (57)

2022

  1. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders

    Viruses, Vol. 14, Núm. 11

2013

  1. The Nature of Progression in Parkinson's Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling

    PLoS ONE, Vol. 8, Núm. 10

2012

  1. Parkinson’s disease: Where are we?

    Parkinson's Disease, Second Edition (CRC Press), pp. 21-27

  2. Placebo effect in Parkinson’s disease

    Parkinson's Disease, Second Edition (CRC Press), pp. 803-810

  3. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor

    European Respiratory Journal, Vol. 40, Núm. 2, pp. 306-312

2011

  1. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease

    Annals of Neurology, Vol. 69, Núm. 5, pp. 803-810

  2. Functional neuroimaging in Parkinson's disease

    Expert Opinion on Medical Diagnostics, Vol. 5, Núm. 2, pp. 109-120

  3. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease

    Brain, Vol. 134, Núm. 11, pp. 3290-3298

  4. Serum vitamin B12 and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion

    Movement Disorders

2010

  1. Dopamine transporter PET in normal aging: Dopamine transporter decline and its possible role in preservation of motor function

    Synapse, Vol. 64, Núm. 2, pp. 146-151

  2. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers

    Movement Disorders, Vol. 25, Núm. 16, pp. 2717-2723

  3. Effects of expectation on placebo-induced dopamine release in Parkinson disease

    Archives of General Psychiatry, Vol. 67, Núm. 8, pp. 857-865

  4. Imaging of compensatory mechanisms in Parkinson's disease

    Current Opinion in Neurology, Vol. 23, Núm. 4, pp. 407-412

  5. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Núm. 12, pp. 2364-2370

  6. Trials of neuroprotective therapies for Parkinson's disease: Problems and limitations

    Parkinsonism and Related Disorders, Vol. 16, Núm. 6, pp. 365-369

  7. Utilidad de las técnicas de neuroimagen funcional en la enfermedad de Parkinson

    Revista de Neurologia, Vol. 50, Núm. SUPPL. 1

2009

  1. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: An in vivo imaging study

    Journal of Neurochemistry, Vol. 109, Núm. 1, pp. 85-92

  2. Dopaminergic function and progression of Parkinson's disease: PET findings

    Parkinsonism and Related Disorders, Vol. 15, Núm. SUPPL. 4

  3. Longitudinal progression of sporadic Parkinson's disease: A multi-tracer positron emission tomography study

    Brain, Vol. 132, Núm. 11, pp. 2970-2979

  4. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

    Neurology, Vol. 72, Núm. 14, pp. 1211-1216